Al-Dawaa Medical Services Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Al-Dawaa Medical Services wird ein jährliches Gewinn- und Umsatzwachstum von 14% bzw. 6.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 12.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 30.4% betragen.

Wichtige Informationen

14.0%

Wachstumsrate der Gewinne

12.1%

EPS-Wachstumsrate

Consumer Retailing Gewinnwachstum19.5%
Wachstumsrate der Einnahmen6.8%
Zukünftige Eigenkapitalrendite30.4%
Analystenabdeckung

Good

Zuletzt aktualisiert27 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Al-Dawaa Medical Services Company (TADAWUL:4163) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Nov 14
Al-Dawaa Medical Services Company (TADAWUL:4163) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Recent updates

Al-Dawaa Medical Services Company (TADAWUL:4163) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Nov 14
Al-Dawaa Medical Services Company (TADAWUL:4163) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Benign Growth For Al-Dawaa Medical Services Company (TADAWUL:4163) Underpins Its Share Price

Sep 24
Benign Growth For Al-Dawaa Medical Services Company (TADAWUL:4163) Underpins Its Share Price

The Returns At Al-Dawaa Medical Services (TADAWUL:4163) Aren't Growing

Jul 29
The Returns At Al-Dawaa Medical Services (TADAWUL:4163) Aren't Growing

Market Still Lacking Some Conviction On Al-Dawaa Medical Services Company (TADAWUL:4163)

Jun 03
Market Still Lacking Some Conviction On Al-Dawaa Medical Services Company (TADAWUL:4163)

Al-Dawaa Medical Services' (TADAWUL:4163) Strong Earnings Are Of Good Quality

May 08
Al-Dawaa Medical Services' (TADAWUL:4163) Strong Earnings Are Of Good Quality

Al-Dawaa Medical Services (TADAWUL:4163) Hasn't Managed To Accelerate Its Returns

Apr 05
Al-Dawaa Medical Services (TADAWUL:4163) Hasn't Managed To Accelerate Its Returns

Al-Dawaa Medical Services (TADAWUL:4163) Has Some Way To Go To Become A Multi-Bagger

Dec 26
Al-Dawaa Medical Services (TADAWUL:4163) Has Some Way To Go To Become A Multi-Bagger

Al-Dawaa Medical Services (TADAWUL:4163) Has Announced A Dividend Of SAR1.25

Sep 03
Al-Dawaa Medical Services (TADAWUL:4163) Has Announced A Dividend Of SAR1.25

Return Trends At Al-Dawaa Medical Services (TADAWUL:4163) Aren't Appealing

Jul 13
Return Trends At Al-Dawaa Medical Services (TADAWUL:4163) Aren't Appealing

Is Al-Dawaa Medical Services Company (TADAWUL:4163) Expensive For A Reason? A Look At Its Intrinsic Value

Jun 22
Is Al-Dawaa Medical Services Company (TADAWUL:4163) Expensive For A Reason? A Look At Its Intrinsic Value

Returns On Capital Signal Tricky Times Ahead For Al-Dawaa Medical Services (TADAWUL:4163)

Apr 10
Returns On Capital Signal Tricky Times Ahead For Al-Dawaa Medical Services (TADAWUL:4163)

Some Shareholders Feeling Restless Over Al-Dawaa Medical Services Company's (TADAWUL:4163) P/E Ratio

Mar 14
Some Shareholders Feeling Restless Over Al-Dawaa Medical Services Company's (TADAWUL:4163) P/E Ratio

Is Al-Dawaa Medical Services Company (TADAWUL:4163) Trading At A 34% Discount?

Dec 08
Is Al-Dawaa Medical Services Company (TADAWUL:4163) Trading At A 34% Discount?

Gewinn- und Umsatzwachstumsprognosen

SASE:4163 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SAR Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20267,1925065148265
12/31/20256,7174444367546
12/31/20246,3143735397823
9/30/20246,187359405666N/A
6/30/20246,000355474703N/A
3/31/20245,850348597836N/A
12/31/20235,741329502726N/A
9/30/20235,742326704848N/A
6/30/20235,612303716881N/A
3/31/20235,485295529743N/A
12/31/20225,372305528778N/A
9/30/20225,212285266651N/A
6/30/20225,163275142519N/A
3/31/20225,119247217561N/A
12/31/20215,034239361670N/A
9/30/20214,977254413649N/A
6/30/20214,958300400644N/A
3/31/20214,932286348566N/A
12/31/20204,962246166378N/A
12/31/20193,962233356515N/A
12/31/20183,797228244392N/A
12/31/20173,376121N/A568N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 4163Das prognostizierte Gewinnwachstum (14% pro Jahr) liegt unter der Sparquote (14.7%).

Ertrag vs. Markt: 4163Die Erträge des Unternehmens (14% pro Jahr) werden voraussichtlich schneller wachsen als der Markt SA (6.4% pro Jahr).

Hohe Wachstumserträge: 4163Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: 4163Die Einnahmen des Unternehmens (6.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt SA (-0.9% pro Jahr).

Hohe Wachstumseinnahmen: 4163Die Einnahmen des Unternehmens (6.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.


Wachstumsprognosen für den Gewinn je Aktie


Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 4163Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (30.4%)


Wachstumsunternehmen entdecken